Inventiva's Stock Rises 5.56% Mid-Day Amid Weakness in the CAC 40
Inventiva stands out from the general apathy of the French market. The stock is up 5.56% mid-day while the CAC 40 is down 0.51%. This divergence reflects a distinct momentum for the biotech, driven by solid quarterly performances accumulated over several months.
Inventiva is trading at €3.79 mid-day, up 5.56% from the previous close of €3.60. This increase contrasts with the general weakness of the French market: over the same period, the CAC 40 has fallen by 0.51% to 8,032.68 points. The extent of this decorrelation highlights a particular dynamic of the biotech stock. In terms of volume, the share of capital traded reaches 0.2%, indicating limited activity despite the price increase. In the longer term, Inventiva has shown remarkable performance: over three months, the stock has increased by 34.81%, and over one year, the increase reaches 57.47%, compared to 8.45% for the CAC 40 over the same annual period.
Recent Developments at Inventiva
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Inventiva has undergone several significant changes in the past two months. At the end of September, the laboratory published its results for the first half of 2025, showing increased losses compared to the previous year. On October 1st, Andrew Obenshain took over as CEO, succeeding co-founder Frédéric Cren. In October, the group launched a new At-The-Market (ATM) program, enhancing its financing capacity. The laboratory also presented several communications at the AASLD The Liver Meeting in October, a major event in the hepatology sector. Furthermore, the group's financing covers its needs until the end of the third quarter of 2026.
Technical Perspective on Inventiva's Stock
From a technical standpoint, the stock is fluctuating between its 50-day moving average at €4.25 and its 200-day moving average at €3.21, confirming a structural upward trend. The RSI is at 51, indicating a balance between buying and selling pressures. The Bollinger Bands place the price near their median envelope, with support at €2.90 and resistance at €4.15. However, the stochastic generates a sell signal, tempering the day's optimism. The major technical resistance threshold is at €5.34.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
